BNN Stock Overview
Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.07 |
| 52 Week High | €4.08 |
| 52 Week Low | €1.42 |
| Beta | 1.2 |
| 11 Month Change | 14.13% |
| 3 Month Change | 83.83% |
| 1 Year Change | -11.27% |
| 33 Year Change | -66.11% |
| 5 Year Change | -66.99% |
| Change since IPO | -70.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNN | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -1.9% | 1.8% | 2.5% |
| 1Y | -11.3% | -0.3% | 8.6% |
Return vs Industry: BNN underperformed the German Chemicals industry which returned -0.3% over the past year.
Return vs Market: BNN underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| BNN volatility | |
|---|---|
| BNN Average Weekly Movement | 21.9% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BNN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BNN's weekly volatility has increased from 13% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 319 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.
BRAIN Biotech AG Fundamentals Summary
| BNN fundamental statistics | |
|---|---|
| Market cap | €69.48m |
| Earnings (TTM) | -€8.77m |
| Revenue (TTM) | €56.26m |
1.2x
P/S Ratio-7.9x
P/E RatioIs BNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNN income statement (TTM) | |
|---|---|
| Revenue | €56.26m |
| Cost of Revenue | €24.98m |
| Gross Profit | €31.29m |
| Other Expenses | €40.06m |
| Earnings | -€8.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 15, 2025
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 55.61% |
| Net Profit Margin | -15.59% |
| Debt/Equity Ratio | 0% |
How did BNN perform over the long term?
See historical performance and comparison